Zoetis (Zoetis (ZTS)) had a rough Thursday. The animal health giant reported first-quarter earnings that missed expectations, and then did something that really spooked investors: it cut its outlook for the rest of the year. The culprit? Pet owners are getting stingy, and competitors are getting aggressive.
The company posted adjusted earnings of $1.53 per share, short of the $1.61 analysts were looking for. Revenue came in at $2.26 billion, also below the $2.31 billion consensus. While sales were up 3% from a year ago, on an organic operational basis—stripping out currency and acquisitions—they were flat. Not great.
Two Very Different Stories in the U.S. and Abroad
Zoetis's business is split roughly evenly between the U.S. and international markets, and the contrast between the two in Q1 is stark.
In the U.S., revenue was $1.1 billion, down 8% from last year. The companion animal segment—think dogs and cats—was the main drag, with sales falling 11%. The company blamed "softer end-market demand and an increasingly competitive landscape." In plain English: fewer people are bringing their pets to the vet, and when they do, they're less willing to spring for the pricey, innovative products that Zoetis is known for.
Overseas, it was a different story. International revenue also hit $1.1 billion, but that was up 17% as reported and 10% on an organic operational basis. Companion animal sales there grew 7% organically, driven by the company's parasiticides like Simparica Trio, plus diagnostics, vaccines, and price increases. The one blemish: lower sales of key dermatology products due to competition.
CEO Kristin Peck: 'A More Challenging Operating Environment'
CEO Kristin Peck didn't sugarcoat things. "The first quarter unfolded in a more challenging operating environment than we anticipated," she said in the earnings release. "Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand for premium innovative products, where Zoetis leads. At the same time, competition intensified across key pet care categories."
Still, she struck an optimistic note: "We are well positioned to deliver our next wave of innovation and remain confident in our ability to deliver sustained value for shareholders."
Guidance Gets Trimmed
That confidence didn't stop Zoetis from lowering its full-year 2026 guidance. The company now expects adjusted earnings of $6.85 to $7.00 per share, down from the previous range of $7.00 to $7.10. The consensus had been $7.02. Revenue guidance was also cut, from $9.83 billion–$10.03 billion to $9.68 billion–$9.96 billion, versus the $9.90 billion consensus.
That's a meaningful downgrade, and the market reacted accordingly.
The Technical Picture: Ugly
Shares of Zoetis were down 20.18% at $88.78 at the time of publication, hitting a new 52-week low. The stock is now trading 23.4% below its 20-day simple moving average of $117.32—a sign of serious weakness. The MACD indicator is below its signal line, suggesting that any upward momentum has evaporated. Unless the stock can reclaim that moving average, the trend looks bearish.
Quality vs. Momentum: A Tale of Two Scores
On MarketDash's quality scorecard, Zoetis scores an 88.12 out of 100, reflecting strong financial health and operational efficiency. That's the good news. The bad news is that its momentum score is much lower, indicating that even a high-quality company can struggle when the market turns against it. The verdict: solid fundamentals, but don't expect a quick rebound unless the headwinds from pet owner spending and competition ease.
For now, Zoetis is a reminder that even the best-run companies can't escape the mood of the consumer—especially when that consumer is watching their wallet.
